Navigation Links
Results of the RIFLE STEACS clinical trial reported at TCT 2011
Date:11/10/2011

SAN FRANCISCO, CA NOVEMBER 10, 2011 Results of a randomized clinical trial suggest that using the transradial approach for angioplasty in patients with ST elevation acute coronary syndrome is preferable to the femoral approach, and should be the recommended access route.

Results of the Radial versus Femoral Randomized Investigation in ST Elevation Acute Coronary Syndrome (RIFLE STEACS) trial were presented today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

Bleeding complications in patients with acute coronary syndrome (ACS) are a significant predictor of mortality and recent data suggest that in these patients, the radial approach could be associated with improved mortality and morbidity.

Researchers in this trial sought to determine whether transradial access for ST elevation Acute Coronary Syndrome (STEACS) treatment is associated with better outcomes when compared to transfemoral approach

The study was a prospective, randomized, parallel group, multi-center trial. Before arterial stick for percutaneous access, all STEACS patients eligible for acute revascularization were randomized (1:1 ratio) to radial or femoral access. 1,001 STEMI patients were enrolled between January 2009 and July 2011 in four high-volume clinical sites in Italy.

The primary endpoint of the study was the rate at 30 days of net adverse clinical events (NACE), a composite of cardiac death, myocardial infarction, stroke, target lesion revascularization or non-coronary artery bypass graft (non-CABG)-related major bleeding. Secondary endpoints were individual components of NACE.

At 30 days, the rate of NACE was significantly lower in the radial group when compared to the femoral group, 13.6% vs. 21.0% respectively. This difference was determined by a reduction of both the major adverse cardiac and cerebrovascular events (MACCE), 7.2% vs. 11.4%, and of bleeding, 7.8% vs. 12.2%. In particular, the rate of cardiac death at 30 days was 9.2% in the femoral group and 5.2% in the radial group.

"Radial access in patients with ST elevation acute coronary syndrome is associated with significant clinical benefits, in terms of both lower morbidity and mortality," said Enrico Romagnoli, MD, PhD, a member of the Interventional Cardiology Unit at Policlinico Casilino in Rome, Italy.

"The radial approach should no longer just be considered a valid alternative to the femoral one, but become the recommended access site for ST elevation acute coronary syndrome," concluded Dr. Romagnoli.


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Results of the PARTNER Trial Cohort B 2-year follow up presented at TCT 2011
2. Results of the PARTNER Trial Cohort A cost effectiveness analysis reported
3. Combination epigenetic therapy clinical trial results
4. Results of the PARIS registry Reported at TCT 2011
5. Results of the TRIGGER-PCI trial reported at TCT 2011
6. Results of rapid gene trial reported at TCT 2011
7. Results of the BRIDGE trial reported at TCT 2011
8. First results of Angiomax (bivalirudin) vs. heparin in transcatheter aortic valve interventions
9. Osteoarthritis results from inflammatory processes, not just wear and tear, Stanford study suggests
10. E-counselling shows dramatic results in lowering blood pressure
11. Less Frequent Mammograms May Lower False-Positive Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... A new ... the world. The Duke Clinical Research Institute (DCRI) and analytics leader SAS will provide ... patient data collected by the Duke University Health System. , The DCRI and ...
(Date:5/4/2016)... , ... May 04, 2016 , ... ... 2016. SS&A teamed up with one of the top website design companies to ... contains informative legal articles related to the law firm's main practice areas. These ...
(Date:5/4/2016)... NC (PRWEB) , ... May 04, 2016 , ... Francesca ... N.C., changed her life forever with a same-day LASIK procedure at Christenbury ... poor eyesight. Dr. Jonathan Christenbury performed her surgery the same day as her in-office ...
(Date:5/4/2016)... ... 04, 2016 , ... Advanced Spine & Sport Medical Rehabilitation Center, which is ... hosting a free seminar on stem cell injections. The seminar is scheduled for Wednesday, ... 4601 Telephone Road, Suite 110, Ventura, CA. There are only 10 seats available. ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... powerful cellular therapy software application that helps blood and marrow transplant (BMT) programs ... Transtem’s initial launch, Mediware has continued to enhance core application features. These enhancements ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... New Jersey , May 4, 2016 ... its successful completion of an alternative public offering (APO). ... wholly owned operating company, Valeritas, Inc. and a private ... common stock at $5.00 per share. Under ... on May 3, 2016, Valeritas Holdings, Inc. will trade ...
(Date:5/4/2016)... 4, 2016 Research ... "Global Actinic Keratosis Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Competitive Landscape Highlights 2016, provides comprehensive insights ... epidemiology, Actinic Keratosis market valuations and forecast, ...
(Date:5/3/2016)... 2016 Research and Markets has ... Cell Therapy Market Outlook 2020" report to their ... , ,Recombinant technology has improved significantly in past years ... developed in coming years. Many cancer drugs have been ... therapies are also expected to be developed with its ...
Breaking Medicine Technology: